Rilonacept Drugs Comprehensive Study by Application (Pediatric, Adult, Geriatric), Treatment (Familial Cold Urticaria Syndrome (FCUS), Muckle-Wells Syndrome (MWS), Neonatal Onset Multisystem Inflammatory Disease (NOMID)), Distribution Channel (Hospital Pharma, Specialty Pharma Retail Stores) Players and Region - Global Market Outlook to 2026

Rilonacept Drugs Market by XX Submarkets | Forecast Years 2022-2027

Summary
Market Segments
Table of Content
List of Table & Figures
Players Profiled

Global Rilonacept Drugs Market Overview:

Rilonacept is a dimeric fusion protein made up of the extracellular ligand-binding domains of the human interleukin-1 receptor segment (IL-1RI) and IL-1 receptor accessory protein (IL-1RAcP) connected in-line to the Fc portion of human IgG1. Rilonacept-based drug ARCALYST is a prescription drug known as an interleukin-1 (IL-1) antagonist. Cryopyrin-associated intermittent syndromes (CAPS), such as familial cold autoinflammatory syndrome (FCAS) and Muckle-Wells syndrome, are treated with this drug (MWS). ARCALYST comes in single-use 20-mL glass vials of a sterile, off-white lyophilized powder. ARCALYST should be reconstituted with 2.3 mL of Sterile Water for Injection per vial. Patients taking ARCALYST have developed serious illnesses, including life-threatening infections and death. Rilonacept is a drug that is used to treat a variety Drugs may have an effect on the immune system, reducing the ability to combat pathogens.

Growth Drivers

Prevalence of Familial cold autoinflammatory syndrome (FCAS)
Rising Geriatric Population

Market Trends

Technical Progress in Medical Industry

Roadblocks

Side Effects and Adverse Reactions

Opportunities

Unexplored Markets

Challenges

Regulatory Approval

Competitive Landscape:

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Kiniksa Pharmaceuticals, Ltd. (Bermuda) and Regeneron Pharmaceuticals (United States). Considering Market by Treatment, the sub-segment i.e. Familial Cold Urticaria Syndrome (FCUS) will boost the Rilonacept Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharma will boost the Rilonacept Drugs market.

On 18th March, 2021 - Received US Food and Drug Administration (FDA) Clearance for ARCALYST (Rilonacept) for the Treatment of Recurrent Pericarditis and Reduction in Risk of Recurrence in Adults and Children 12 Years and Older.

European Medicines Agency, EU/3/07/456; Revoked - Orphan Designation Granted to Regeneron UK Ltd., For Its Rilonacept Drug Was Withdrawn by the European Commission on 24 October 2012. The Drug Is No Longer Valid for Sale Across EU. and United States, Food and Drug Administration �ARCALYST/Rilonacept� Label; Provides a Comprehensive List of Procedures Regarding the Usage, Indications and Dosage Requirements Based on the Patient Profile of ARCALYST Injections Across US.

What Can be Explored with the Rilonacept Drugs Market Study

 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Rilonacept Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Rilonacept Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Rilonacept Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Rilonacept Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants and Investors, API Providers, Rilonacept Drugs Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Market Segments

Report Objectives / Segmentation Covered

By Application

Pediatric
Adult
Geriatric

By Treatment

Familial Cold Urticaria Syndrome (FCUS)
Muckle-Wells Syndrome (MWS)
Neonatal Onset Multisystem Inflammatory Disease (NOMID)

By Distribution Channel

Hospital Pharma
Specialty Pharma Retail Stores

By Regions

South America
- Brazil
- Argentina
- Rest of South America
Asia Pacific
- China
- Japan
- India
- South Korea
- Taiwan
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- Italy
- United Kingdom
- Netherlands
- Rest of Europe
MEA
- Middle East
- Africa
North America
- United States
- Canada
- Mexico

Table of Content

List of Tables & Figures

List of Tables

List of Figures

Figure 1. Porters Five Forces
Figure 2. Supply/Value Chain
Figure 3. PESTEL analysis
Figure 4. Global Rilonacept Drugs: by Application USD Million (2015-2020)
Figure 5. Global Rilonacept Drugs: by Treatment USD Million (2015-2020)
Figure 6. Global Rilonacept Drugs: by Distribution Channel USD Million (2015-2020)
Figure 7. South America Rilonacept Drugs Share (%), by Country
Figure 8. Asia Pacific Rilonacept Drugs Share (%), by Country
Figure 9. Europe Rilonacept Drugs Share (%), by Country
Figure 10. MEA Rilonacept Drugs Share (%), by Country
Figure 11. North America Rilonacept Drugs Share (%), by Country
Figure 12. Global Rilonacept Drugs share by Players 2020 (%)
Figure 13. BCG Matrix for key Companies
Figure 14. Kiniksa Pharmaceuticals, Ltd. (Bermuda) Revenue, Net Income and Gross profit
Figure 15. Kiniksa Pharmaceuticals, Ltd. (Bermuda) Revenue: by Geography 2020
Figure 16. Regeneron Pharmaceuticals (United States) Revenue, Net Income and Gross profit
Figure 17. Regeneron Pharmaceuticals (United States) Revenue: by Geography 2020
Figure 18. Global Rilonacept Drugs: by Application USD Million (2021-2026)
Figure 19. Global Rilonacept Drugs: by Treatment USD Million (2021-2026)
Figure 20. Global Rilonacept Drugs: by Distribution Channel USD Million (2021-2026)
Figure 21. South America Rilonacept Drugs Share (%), by Country
Figure 22. Asia Pacific Rilonacept Drugs Share (%), by Country
Figure 23. Europe Rilonacept Drugs Share (%), by Country
Figure 24. MEA Rilonacept Drugs Share (%), by Country
Figure 25. North America Rilonacept Drugs Share (%), by Country

Companies Mentioned

List of companies from research coverage that are profiled in the study

Kiniksa Pharmaceuticals, Ltd. (Bermuda)
Regeneron Pharmaceuticals (United States)

Select User Access Type

Single User
$ 3450
Corporate User
$ 6500

Key Highlights of Report

Apr 2021 220 Pages 88 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing

Check Discount Now

Global Rilonacept Drugs Market Quantitative research analysis

Global Rilonacept Drugs Market Qualitative Industry Analysis

DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?

"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Rilonacept Drugs Market Report?

Have a Query? Click Here

Rilonacept Drugs Market by XX Submarkets | Forecast Years 2022-2027

Report Objectives / Segmentation Covered

Talk to Our Experts

Want to Customize Study?

Know More About Global Rilonacept Drugs Market Report?

Other Related Reports